SUPN SUPERNUS PHARMACEUTICALS, INC.
FY2025 10-K
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed its fiscal year 2025 10-K annual report with the SEC on Mar 2, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: pharmaceutical development and commercialization of prescription drugs
- • New emphasis on compliance with 2025 Executive Orders targeting drug price transparency, expanded Medicare negotiations, and site-neutral payment policies
Management Discussion & Analysis
- • Total revenues $718.95M, up 9% YoY from $661.82M driven by Qelbree $304.65M (+26%) and new launch ONAPGO $17.25M
- • Operating loss driven by SG&A $485.56M (51% increase YoY) and intangible amortization $89.46M (+15%); net loss ($38.55M) vs net income $73.87M in 2024
Risk Factors
- • Legal risk from potential claims or fines related to 2021 ransomware attack, fines or costs not yet estimable
- • Operational risk from increased ongoing IT security investments initiated post-2021 ransomware incident
Financial SummaryXBRL
Revenue
$719M
Net Income
-$39M
Operating Margin
-8.7%
Net Margin
-5.4%
ROE
-3.6%
Total Assets
$1.5B
EPS (Diluted)
$-0.68
Operating Cash Flow
$47M
Source: XBRL data from SUPERNUS PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SUPERNUS PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.